Detalle de: First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases
| Title | First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases |
| Abstract |
A novel inhibitor of interactions between signaling proteins in T cells demonstrates promising preventive and therapeutic effects in several models of autoimmune disease. |
| Apa Reference | Borroto, A., Reyes-Garau, D., Jiménez, M.A., Carrasco, E., Moreno, B., Martínez-Pasamar, S., Cortés, J.R., Perona, A., Abia, D., Blanco, S., Fuentes, M., Arellano, I., Lobo, J., Heidarieh, H., Rueda, J., Esteve, P., Cibrián, D., Martinez-Riaño, A., Mendoza, P., Prieto, C., Calleja, E., Oeste, C.L., Orfao, A., Fresno, M., Sánchez-Madrid, F., Alcamí, A., Bovolenta, P., Martín, P., Villoslada, P., Morreale, A., Messeguer, A. & Alarcon, B. (2016). First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Science Translational Medicine, 8(370). 10.1126/scitranslmed.aaf2140 |
| Doi | 10.1126/scitranslmed.aaf2140 |
| Publication Date | 21 Dec 2016 |
| Publication Type | Article |
| Researcher | David Ángel Abia Holgado |
| Ontology | Drug Discovery and design |
| Research Groups | |
| Tools |